The 35th CINP World Congress of Neuropsychopharmacology

Presentation information

Print

[CINP2024] Spotlight Session

CINP2024 » Spotlight Session

Spotlight Session 9
Introducing CINP's Global Networking Communities

Sat. May 25, 2024 1:00 PM - 2:00 PM Room 5 (G409)

Chair: Joseph Zohar (National Post-Trauma Center, Research Foundation by the Sheba Medical Center, Israel)

Overview:
CINP has recently formed six Global Networking Communities (GNCs) to provide a collaborative and inclusive environment for those with shared subspecialist interest to network with global peers, develop and obtain funding for collective research projects, pursue educational goals, raise awareness of new treatment modalities and build symposia proposals for CINP World Congresses.
Membership of the GNCs is open to all CINP members in good standing, who are eligible to join a maximum of two communities. The first six GNCs to be formed cover the following subspecialist fields:
Difficult to Treat Depression, Digital Intervention, Fast Acting Medications/Psychedelics, Neuromodulation, OCD Spectrum, Precision Psychiatry.
In this session, four of the GNC leaders will introduce their communities and provide an overview of the activities they have planned for the next 12 months.
Audience members will have the opportunity to ask questions and to propose areas of activity for the various communities.

[SS9-1] Psychedelic Pharmacology GNC

*Gabriella Gobbi1 (1. McGill University)

Prof Gabriella Gobbi is a Professor in the Department of Psychiatry at McGill University, Montreal. She leads a laboratory of basic science (Neurobiological Psychiatry Unit) and works as a Staff Psychiatrist at the Mood Disorder Clinic of the McGill University Health Center.
Her laboratory focuses on understanding the pathophysiology of major depression and sleep related disorders and in the discovery of new treatments and cures for them. She is particularly known for her work on Psychedelics for Anxiety, the association between cannabis use and depression in adolescence and the use of Melatonin MT2 receptor agonsists for pain and insomnia.
Dr. Gobbi is author of more than 90 highly cited manuscripts in high impact journals, 20 book chapters, one book and holds two international patents in psychopharmacology. She has received several fellowships, won many prizes and serves as a reviewer/editor for many journals.

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.

Password